News | May 02, 2026
Merck posts mixed Q1 2026 results as blockbuster drugs drive growth
But acquisition charges drag earnings into loss
But acquisition charges drag earnings into loss
The company posted revenue of Rs. 703 crore in Q4 FY26
The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
The company allocated €56 million to research and development for next-generation line solutions
The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy
The company reported net revenue of SEK 13.5 million for the full year 2025
Move amid evidence of widespread reporting gaps
Safety was equally impressive. ENV-294 was well tolerated
Subscribe To Our Newsletter & Stay Updated
